Spiropiperidine CCR5 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5401-5406

  Rotstein, David M ^a   Gabriel, Stephen D ^a   Makra, Ferenc ^a   Filonova, Lubov ^a   Gleason, Shelley ^a   Brotherton Pleiss, Christine ^a   Setti, Lina Q ^a   Trejo Martin, Alejandra ^a   Lee, Eun Kyung ^a   Sankuratri, Surya ^a   Ji, Changhua ^a   deRosier, Andre ^a   Dioszegi, Marianna ^a   Heilek, Gabrielle ^a   Jekle, Andreas ^a   Berry, Pamela ^a   Weller, Paul ^a   Mau, Cheng I ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Anti HIV 1; Antiviral; CCR5 antagonist; Chemokine; Spiropiperidine

Indexed keywords

1 OXA 3,9 DIAZASPIRO[5.5]UNDECAN 2 ONE DERIVATIVE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; PIPERIDINE DERIVATIVE; SPIRO COMPOUND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAXIMUM PLASMA CONCENTRATION; MONKEY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CACO-2 CELLS; DOGS; HAPLORHINI; HUMANS; PIPERIDINES; RATS; RECEPTORS, CCR5; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68949105607     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.122     Document Type: Article

References (13)

1. Wainberg M.A., and Jeang K.-T. BMC Med. 6 (2008) 1
2. Kuhmann S.E., and Hartley O. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 425
3. Kuritzkes D., Kar S., and Kirkpatrick P. Nat. Rev. Drug Disc. 7 (2008) 15
4. Turner J.E., Steinmetz O.M., Stahl R.A., and Panzer U. Mini-Rev. Med. Chem. 7 (2007) 1089
5. Habashita H., Kikubo M., Hmano S., Hamanaka N., Masaaki T., Shibayama S., Tada H., Sagawa K., Fukushima D., Maeda K., and Mitsuya H. J. Med. Chem. 49 (2006) 4140
6. McIntyre J.A., and Castñer J. Drugs Future 29 (2004) 677
7. Palani A., Shapiro S., Clader J.W., Greenlee W.J., Cox K., Strizki J., Endres M., and Baroudy B.M. J. Med. Chem. 44 (2001) 3339
8. For assay protocols see: Melville, C.R.; Rotstein, D. M. WO2008119663.
9. The thresholds above which intrinsic mircrosomal clearance values were considered to be high were ≥90 μl/min/mL for RLM and ≥35 μl/min/mL for HLM. These scaled to in vivo clearance values ≥70% of liver blood flow using the well-stirred model. Intrinsic microsomal clearance values corresponding to ≤30% of liver blood flow (≤15 μl/min/mL for RLM and ≤6.5 μl/min/mL for HLM) were considered to be low.
10. Obach R.S. Curr. Opin. Drug Discovery Dev. 4 (2001) 36
11. Ernst J., Dahl R., Lum C., Sebo L., Urban J., Miller S.G., and Lundström. J. Bioorg. Med. Chem. Lett 18 (2008) 1498
12. The relatively low exposure observed in rat was due to active transport, in addition to metabolic clearance. Pre-treatment with the P-gp inhibitor elacridar gave higher exposures due to reduced biliary excretion and intestinal secretion. Saturation of transporter effects upon higher dosing also gave improved exposures.
13. For more detailed experimental data, see: Gabriel, S. D.; Rotstein, D. M. US Patent 2005, 176703, Ref. 8.